All these studies demonstrated that using the DNA sequence spanning the BCR and ABL1 gene breakpoints as the target for CML monitoring has several advantages: genomic DNA is more stable, the BCR-ABL1+ cell number is directly measured, and laboratory standardization is simpler. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.